ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APLleukemic phenotype SUPPLEMENTARY DATA
MATERIALS AND METHODS

Cell line culture
The human APL derived cell line NB4 carrying the t(15;17) translocation and expressing the PML/RARA fusion protein was purchased from the American Tissue Culture Collection (ATCC, Rockville, MD) and was cultured at 37°C in a humidified atmosphere of 5% CO2 in air, in RPMI medium (GIBCOBRL, Grand Island, NY, USA), supplemented with 10% fetal bovine serum (FBS) (GIBCO-BRL, Grand Island, NY, USA), 20 mM Hepes. Cell viability was determined via trypan blue assay, and only cultures with 95% viability were used for subsequent in vitro experiments.
RESULTS
Generation of ΔNp73-PML/RARA double mutant murine cells
The human coding sequence of the ΔNp73 gene was stably overexpressed in murine hematopoietic BM cells from hCG-PML/RARA transgenic mice and its wild-type counterpart using a lentiviral vector in which ΔNp73 expression was driven by the MSCV promoter (Supplementary Figure 1A) . To determine the efficiency of infection, GFP-positive cells were quantified by flow cytometry. Infected cells were highly purified based on the expression of GFP protein. Similar infection rates were reached in both hCG-PML/RARA and WT cells (Supplementary Figure 1B) . Additionally, cytospin preparations stained with DAPI were used for fluorescence evaluation (Supplementary Figure 1C) . In order to confirm if the infection of ΔNp73 gene had efficiently resulted in a translation of its protein, transfected murine BM cells were lysed and protein lysates prepared using previously described methods. As shown in Supplementary Figure  1D , cells infected with pMEG-ΔNp73 lentivirus efficiently expressed the ΔNp73 protein. Next, we took advantage of the PML/RARA-positive NB4 cell line to demonstrate the ratio between truncated (ΔNp73) and transcriptionally active (TAp73) isoforms in our lentiviral model (Supplementary Figure 2) .
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